Glympse Bio – Tunable Biosensors for Noninvasive Disease Monitoring

Dr. Caroline Loew, President and CEO of Glympse Bio, a clinical stage biotechnology company, discusses the company’s development of tunable biosensors capable of noninvasive disease monitoring in NASH, other fibrotic diseases, and Non-Small Cell Lung Cancer. They serve as a repeatable alternative to biopsy, allowing patients to be monitored more frequently without the need for a surgical procedure.

Caroline J. Loew, Ph.D., Pesident & Chief Executive Officer. Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered, and integrated teams. She has broad experience integrating science, business, and the clinic to deliver differentiated value to patients. Most recently, she was Vice President, Head R&D Strategy, and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning inmmune-oncology, immunoscience, fibrosis, and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory, and drug development. An organic chemist by training, Caroline studied as an undergraduate and postgraduate at Imperial College, London.